{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T19:22:04Z","timestamp":1779045724562,"version":"3.51.4"},"reference-count":11,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2018,12,16]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>New guidelines have been produced for the management of primary biliary cholangitis, an infrequent but nonetheless important autoimmune liver disease. We provide a succient commentary and overview of the key features of disease management that arise from these recent guideline recommendations, with a focus on therapy with licensed agents (ursodeoxycholic acid and obeticholic acid) as well as personalised management of disease complications and associated symptoms.<\/jats:p>","DOI":"10.1136\/flgastro-2018-101109","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T17:19:25Z","timestamp":1547054365000},"page":"316-319","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Guideline review: British Society of Gastroenterology\/UK-PBC Primary Biliary Cholangitis treatment and management guidelines"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6054-569X","authenticated-orcid":false,"given":"Jorn C","family":"Goet","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon M","family":"Hirschfield","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"2025090708453087000_10.3.316.1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt308"},{"key":"2025090708453087000_10.3.316.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"2025090708453087000_10.3.316.3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315259"},{"key":"2025090708453087000_10.3.316.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.029"},{"key":"2025090708453087000_10.3.316.5","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5403"},{"key":"2025090708453087000_10.3.316.6","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"2025090708453087000_10.3.316.7","doi-asserted-by":"crossref","unstructured":"Carbone M , Sharp SJ , Flack S , et al . The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016;63.doi:10.1002\/hep.28017","DOI":"10.1002\/hep.28017"},{"key":"2025090708453087000_10.3.316.8","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.216"},{"key":"2025090708453087000_10.3.316.9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"2025090708453087000_10.3.316.10","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31880"},{"key":"2025090708453087000_10.3.316.11","doi-asserted-by":"crossref","unstructured":"Moctezuma-Velazquez C , Saffioti F , Tasayco-Huaman S , et al . Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol 2018. doi: 10.1038\/s41395-018-0265-7. [Epub ahead of print 12 Oct 2018].doi:10.1038\/s41395-018-0265-7","DOI":"10.1038\/s41395-018-0265-7"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2018-101109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:45:37Z","timestamp":1757259937000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2018-101109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,6,10]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/flgastro-2018-101109"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2018-101109","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]}}}